KURA Kura Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1422143 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-35.0%
TTM EPS YoY-33.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-394.3%
Net margin-369.3%
FCF margin-112.4%
EBITDA margin-392.5%
Returns
ROE-224.9%
ROA-48.2%
ROIC (approx.)-389.8%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets96.8%
Debt / equity0.55x
Current ratio3.60x
Interest coverage-227.12x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio-34.1%
Payout ratio—
Capex / revenue4.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $67.48M | $53.88M | $0 | — | — |
| R&D expense | $251.07M | $169.97M | $115.23M | $92.81M | $84.72M |
| SG&A expense | $119.98M | $77.11M | $50.57M | $47.05M | $46.54M |
| Operating income | -$303.63M | -$193.19M | -$165.80M | -$139.87M | — |
| Interest expense | $1.51M | $1.62M | $1.55M | $229,000 | $414,000 |
| Pretax income | -$278.37M | -$171.97M | -$152.63M | -$135.84M | — |
| Income tax | $297,000 | $2.02M | $0 | $0 | $0 |
| Net income | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -$130.47M |
| EBITDA | -$302.60M | -$192.35M | -$164.96M | -$139.11M | — |
| EPS (basic) | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 |
| EPS (diluted) | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 |
| Weighted avg. shares (diluted) | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M |
| Balance sheet | |||||
| Cash & equivalents | $149.10M | $224.46M | $37.32M | $51.80M | $90.67M |
| Short-term investments | $518.14M | $502.93M | $386.64M | $386.18M | $427.29M |
| Receivables | $8.80M | $2.06M | — | — | — |
| Inventory | $413,000 | $0 | — | — | — |
| Current assets | $708.66M | $744.83M | $432.48M | $446.43M | $522.29M |
| PP&E, net | $7.86M | $1.68M | $1.86M | $2.54M | $2.67M |
| Total assets | $738.36M | $760.16M | $448.94M | $456.31M | $534.05M |
| Current liabilities | $116.97M | $78.71M | $35.26M | $24.06M | $22.45M |
| Short-term debt | $0 | $2.61M | — | — | — |
| Long-term debt | $9.71M | $6.92M | $9.33M | $9.16M | — |
| Total debt | $9.71M | $9.52M | $9.33M | $9.16M | — |
| Total liabilities | $564.23M | $346.52M | $51.66M | $36.03M | $27.44M |
| Shareholders' equity | $174.13M | $413.64M | $397.27M | $420.28M | $506.61M |
| Net debt | -$139.39M | -$214.94M | -$27.99M | -$42.64M | — |
| Shares outstanding | 87.86M | 78.23M | 74.35M | 68.31M | 66.57M |
| Cash flow statement | |||||
| Operating cash flow | -$64.06M | $134.32M | -$124.82M | -$110.06M | -$104.55M |
| Capital expenditure | $6.64M | $472,000 | $168,000 | $626,000 | $1.15M |
| Free cash flow | -$70.70M | $133.84M | -$124.99M | -$110.69M | -$105.70M |
| Investing cash flow | -$13.10M | -$101.59M | $15.56M | $32.63M | -$126.83M |
| Financing cash flow | $1.79M | $154.42M | $94.78M | $38.56M | -$3.44M |
| Depreciation & amortization | $1.03M | $848,000 | $849,000 | $759,000 | $558,000 |
| Stock-based compensation | $37.11M | $33.90M | $28.08M | $26.32M | $23.58M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.